Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
NurExone Biologic Inc.
NRXBF
Primary Symbol:
V.NRX
Healthcare
Biotechnology
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following...
spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (TSXV:NRX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 08, 2024 4:05pm
New Press Release - NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel
Joins exclusive group of innovative companies headquartered on Technion Campus TORONTO and HAIFA, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, finalized today a lease and...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 01, 2024 4:04pm
New Press Release - NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
TORONTO and HAIFA, Israel, March 01, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Ina Sarel, the Head of CMC, Quality and Regulatory Affairs at NurExone, will be...
read article.
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 20, 2024 4:05pm
New Press Release - NurExone's Intellectual Property Portfolio Expands
Innovations and know-how in exosome production suited for many clinical applications TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 14, 2024 4:20pm
New Press Release - NurExone Launches Licensing Efforts for ExoTherapy Platform
Huge opportunity for development of nanodrugs for wide variety of clinical indications TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company, announced today the commencement of...
read article.
(6)
•••
ElliotGH
X
View Profile
View Bullboard History
Post by
ElliotGH
on Feb 12, 2024 9:42am
IP Asset Expansion - Commercial Potential (TSXV: NRX)
IP Asset Expansion - Commercial Potential (TSXV: NRX, FSE: J90, NRX.V) https://youtu.be/q_CxVNERw0o?si=-WLz7f1l9Vu8bA40
(182)
•••
Oldschool2022
X
View Profile
View Bullboard History
Post by
Oldschool2022
on Feb 09, 2024 8:42am
Can we break $1 today? Cutting edge technology here!
We have an ambitious long-term goal – Reverse the devastating effects of nervous system injuries. Finally. Our technology to achieve this is a next generation of therapy, ExoTherapy
...more
(182)
•••
Oldschool2022
X
View Profile
View Bullboard History
Post by
Oldschool2022
on Feb 09, 2024 6:15am
Up 42.7% on the Frankfurt over night trading.
This rocket has launched. Last trading at .645 Euros or .93 Canadian. Can we make this the 5th straight green day this week? News has to be close. Their spinal therapy is world changing. Hold tight
...more
(182)
•••
Oldschool2022
X
View Profile
View Bullboard History
Post by
Oldschool2022
on Feb 08, 2024 10:34pm
Litchfield Hills research has a $4 price target on NurExone
We should easily hit 1.20-$1.30 tomorrow. The trend is your friend. Looking at the chart something big is coming. This could keep moving for a few weeks. Wouldn't that be nice.
(182)
•••
Oldschool2022
X
View Profile
View Bullboard History
Post by
Oldschool2022
on Feb 08, 2024 8:57pm
This stock has moved from .32 to .83 per share in 2 days.
Top 4 Spinal Injury Stocks for 2024 (NRX.V, NVRO, SYK, BSX) January 22, 2024 at 05:01 am EST Share (via NewsDirect) Investors eyeing dynamic opportunities in healthcare
...more
(6)
•••
ElliotGH
X
View Profile
View Bullboard History
Post by
ElliotGH
on Feb 05, 2024 12:16pm
$NRX gains traction in Europe with Orphan drug designation
NurExone gains traction in Europe with Orphan drug designation awarded by regulator (TSXV: NRX) (FSE: J90) (NRX.V) https://10xalerts.com/nurexone-gains-traction-in-europe-with-orphan-drug
...more
(1155)
•••
Pandora
X
View Profile
View Bullboard History
Comment by
Pandora
on Feb 04, 2024 12:37pm
RE:NurExone Biologic Inc is Poised to Capture Significant Value
Anyone following NGEN as well?
(8)
•••
Brice978
X
View Profile
View Bullboard History
Post by
Brice978
on Jan 22, 2024 2:02pm
Top 4 Spinal Injury Stocks for 2024 ((TSXV: NRX, NYSE: NVRO,
Top 4 Spinal Injury Stocks for 2024 ((TSXV: NRX, NYSE: NVRO, NYSE: SYK, NYSE: BSX) https://www.marketscreener.com/quote/stock/NUREXONE-BIOLOGIC-INC-49479308/news/Top-4-Spinal-Injury-Stocks-for
...more
(10)
•••
Mathew177
X
View Profile
View Bullboard History
Post by
Mathew177
on Jan 16, 2024 11:28am
NurExone Biologic Inc is Poised to Capture Significant Value
NurExone Biologic Inc. is Poised to Capture Significant Value (TSXV: NRX) (FSE: J90) (NRX.V) https://10xalerts.com/nurexone-biologic-inc-is-poised-to-capture-significant-value-tsxv-nrx-fse
...more
(8)
•••
Brice978
X
View Profile
View Bullboard History
Post by
Brice978
on Dec 05, 2023 2:26pm
Episode #1: NurExone Podcast - The Neurosurgeon's Perspectiv
https://www.youtube.com/watch?v=rcTf-3Do8c8
(2)
•••
RealREIT$
X
View Profile
View Bullboard History
Post by
RealREIT$
on Dec 01, 2023 11:59am
New Highs
Hitting $0.315 now from $0.18 when I got in. Should hit $0.345 next...
Prev
1
2
3
4
5
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden